Ansa Biotechnologies closes $68M Series A to commercialise enzymatic DNA synthesis

Ansa Biotechnologies/Enzymatic long-DNA synthesis

Ansa raised a $68M Series A led by Northpond Ventures to build high-throughput synthesizers and launch a DNA synthesis service. Its method, first published by the founders in Nature Biotechnology in 2018, tethers each nucleotide to a template-independent polymerase so the enzyme adds exactly one base per cycle. The company argues this avoids the harsh chemistry that limits the length and accuracy of conventional DNA synthesis.

• Brought total private funding to $82M.
• Investors included RA Capital, Mubadala Capital and Horizons Ventures.
• Also working with Microsoft on enzymatic reagents for DNA data storage.